# Hemab Therapeutics Holdings Inc. (COAG) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $44.41, market value $2.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Hemab Therapeutics Holdings Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.6×**. The shares trade at 4.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -3.5%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 36.2%**. 36.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): -31.3%**. Earnings per share fell 31.3%.

## Financial health
- **Current ratio: 18.03** (quick 18.03). Current assets cover the next year's liabilities 18.03 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Hemab Therapeutics Holdings Inc. does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -19.9%** (93.1% above the low). Trading 20% below its 52-week high.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.70** (volatility 95%). Beta of 1.70 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=COAG · Page: https://foliofundamentals.com/stocks/coag

Not investment advice.